Robert E. Dudley - 12 Dec 2021 Form 4 Insider Report for Clarus Therapeutics Holdings, Inc. (CRXT)

Role: Chief Executive Officer, Director
Signature: /s/ Steven A. Bourne, attorney-in-fact
Issuer symbol: CRXT
Transactions as of: 12 Dec 2021
Net transactions value: $0
Form type: 4
Filing time: 14 Dec 2021, 18:00:40 UTC
Previous filing: 13 Sep 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRXT	Common Stock	Award	$0	+135,000	+2957%	$0.000000	139,566	12 Dec 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRXT	Stock Option (Right to Buy)	Award	$0	+337,500		$0.000000	337,500	12 Dec 2021	Common Stock	337,500	$4.78	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person was granted a Restricted Stock Unit under the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan") for 135,000 shares on 12/12/2021, of which 25% vest on 9/9/2022, and the remaining shares vest in 36 equal monthly installments thereafter subject to the Reporting Person continuing to have a service relationship as of each such vesting date.
F2	These options were granted under the 2021 Plan and vest (i) 25% on 9/9/2022 and (ii) with the remainder vesting in 36 equal monthly installments thereafter subject to the Reporting Person continuing to have a service relationship as of each such vesting date.